Live Feed

Small business owners are the backbone of America. Owner is building AI to do the work they have never been able to afford.SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Owner is on a mission to arm millions of local business owners with the AI they need to take on Goliaths. It's starting with restaurants. Today, Owner announced it has raised $240 million and reached a $2.3 billion valuation. Growth Equity at Goldman Sachs Alternatives led the financing. Existing investors Meritech, Redpoint, Headline, and Jack Altman also participated. Owner is the AI CMO and CTO for local businesses. It builds and runs their technology and mark

NEW YORK, Aug. 28, 2026 /PRNewswire/ -- Bullish, an institutionally focused global digital asset platform that provides market infrastructure and information services, today announced its strategic entry into middle-market AI infrastructure financing through a $100 million stablecoin-based liquidity facility provided to USD.AI. This major investment will power USD.AI's premier GPU financing ecosystem, empowering them to lend capital directly against high-performance computing assets. With the facility, Bullish is targeting a capital-intensive sector that has rapidly emerged as one of the largest in private credit, with a scale that eclipses legacy debt markets such as auto loans and home equ

Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in addition to its established A1C and weight loss benefitsIt is estimated that as many as one in three adults in the U.S. with type 2 diabetes have undetected cardiovascular disease1INDIANAPOLIS, Aug. 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal hear

Altria Group, Inc. (NYSE:MO) is pleased to announce that Steven W. Presley joined our Board of Directors (Board) on August 27, 2026. Mr. Presley is Chief Executive Officer of Refresco Benelux B.V., a global independent beverage solutions provider, a position he has held since August 2025. Mr. Presley previously served as Executive Vice President and Chief Executive Officer Zone Americas, Nestlé S.A., a global food and beverage company, from October 2024 to April 2025, and as Executive Vice President and Chief Executive Officer Zone North America, Nestlé S.A., from January 2021 to October 2024. Mr. Presley served in a variety of other senior roles since joining Nestlé USA in 1997, includin

Principal partnership with Chelsea FC puts Circle and USDC Brands on Men's, Women's and Academy shirts beginning with the 2026/27 season Chelsea Football Club today announced a landmark partnership with Circle Internet Group, Inc. (NYSE:CRCL), one of the world’s leading internet financial platform companies. The new partnership will see Circle become a Principal Partner of Chelsea FC and Official front-of-shirt partner beginning with the 2026/27 season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828998650/en/ The partnership comes at a pivotal moment for the world. Stablecoins are moving from early adoption toward the m

N-able, Inc. (NYSE:NABL), a global cybersecurity company delivering business resilience, today announced that its Board of Directors has approved an increase of $50 million to the previously authorized share repurchase program of up to an aggregate of $75 million of shares of its common stock announced in March 2025. N-able had $45 million remaining as of June 30, 2026 from the previous authorization."This increased authorization reflects our conviction that repurchasing shares at current levels represents an attractive use of capital and a compelling opportunity to create shareholder value over the long-term," said N-able CFO Tim O’Brien. "As threats continue to evolve and our customers' se

SHANGHAI, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Chagee Holdings Limited (NASDAQ:CHA) ("Chagee" or the "Company"), a leading premium tea drinks brand serving healthy and delicious freshly-made tea drinks, today announced its unaudited financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Operational Highlights1 As of June 30, 2026, there were 7,639 teahouses within the Company’s teahouse network in Greater China and overseas, representing an 8.5% increase in the number of teahouses as of June 30, 2025.Total GMV generated in the second quarter of 2026 was RMB7,660.3 million. Geographically, total GMV generated in overseas markets was RMB504.0 million in the seco

CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the "IR Agreement"). The IR Agreement had a 90-day term commencing May 18, 2026 and provided for 10 individual marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable in advance. The fee was fully earned upon receip

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. "Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition," said Martin Brenner, Ph.D

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients with connective tissue disease, in which underlying vascular remodeling and endothelial dysfunction may be accelerated, making PAH more difficult to treat TETON presentations include analyses showing that nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit compared to placebo in idiopathic pulmonary fibrosis (IPF) patients Additional presentations feat

Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus systems bring cSound™ imaging with capabilities designed for routine echocardiography, comprehensive cardiac imaging and interventional care GE HealthCare (NASDAQ:GEHC) today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer1, Vivid™ Advanced1 and Vivid™ Focus1 – each designed to address distinct imaging and workflow needs across a range of cardiology care settings. The systems will be showcased at the European Society of Cardiology (ESC) Congress 2026, taking place August 28–31 in Munich, Germany. The number of people living with cardiovascular disease worldwide has doubled since 1991.2 As car

Dollar General Corporation (NYSE:DG) today announced that Rhonda Taylor, the Company’s Executive Vice President and General Counsel, will retire from the Company. To support a seamless leadership transition, Taylor will remain in her current role through December 6, 2026, then serve in a senior advisory role through at least April 2, 2027. Kelly Collier, Dollar General’s current Senior Vice President, Assistant General Counsel for Business Law will succeed Taylor and be promoted to EVP, General Counsel effective December 7, 2026. "For years, Rhonda has been far more than our General Counsel. She has served as a trusted advisor, respected leader, and strategic business partner who helped p

Caleres (NYSE:CAL), a market-leading portfolio of consumer-driven footwear brands, today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.07 per share to be paid on September 25, 2026, to shareholders of record as of September 11, 2026.Caleres has paid consecutive quarterly dividends for over a century, reflecting a core commitment to shareholders and a testament to the company’s financial strength.About CaleresCaleres is a market-leading portfolio of global footwear brands that includes Famous Footwear, Sam Edelman, Stuart Weitzman, Allen Edmonds, Naturalizer, Vionic, and more. Our products are available virtually everywhere – in the ~1,000 retail s

4 - WEIBO Corp (0001595761) (Issuer)

HONG KONG and SINGAPORE, Aug. 28, 2026 (GLOBE NEWSWIRE) -- MoneyHero Limited (NASDAQ:MNY) ("MoneyHero" or the "Company"), a leading tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia, today announced that it will release its second quarter 2026 results on Friday, September 11, 2026 before market opens and will hold a related conference call to discuss the results at 8:00 a.m. EDT (or 8:00 p.m. Hong Kong / Singapore time) on the same day. Investors and other interested parties may listen to the call by clicking on the registration link for the webcast or audio conference at: Webcast: https://edge.m

3 - Northann Corp. (0001923780) (Issuer)

Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - NexGen Energy Ltd. (TSX:NXE) (NYSE:NXE) (ASX: NXG) ("NexGen" or the "Company") is pleased to announce that it will host its 2026 Investor Day on: Date: Tuesday, 1 September 2026Time: 8.00 A.M. Eastern Time, 10.00 P.M Australian Eastern Standard Time, same day. The pre-recorded virtual event will feature presentations from NexGen's senior leadership and technical team, providing a detailed overview of the construction plan and activities at the Company's 100% owned Rook I Project. The webcast can be accessed through registration at: https://reg.lumiengage.com/nexgen-investor-day-2026. A link to the webcast will be made availa

FORT WORTH, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE:RRC) today announced that its Board of Directors declared a quarterly cash dividend on its common stock for the third quarter. A dividend of $0.10 per common share is payable on September 25, 2026 to stockholders of record at the close of business on September 11, 2026. RANGE RESOURCES CORPORATION (NYSE:RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas.  More information about Range can be found at www.rangeresources.com. SOURCE:Range Resources Corporation   Range Investor Contact:   Laith S

Expanded agreement combines Pega’s AI and workflow platform with Coforge’s consulting, engineering and managed-services capabilities to help enterprises modernise legacy systems, scale AI adoption and deliver measurable business outcomes The expanded agreement builds on two decades of collaboration between Coforge and Pega. Coforge Limited (NSE: COFORGE), a global AI-native engineering services leader, today announced the expansion of its strategic partnership with Pegasystems Inc. (NASDAQ:PEGA), the enterprise AI software company for mission-critical work. The partnership allows Coforge to build, package, brand, and commercially deliver Pega-powered offerings, strengthening the abil

BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions. Transaction reflects Teva’s targeted business development approach focused on strategic fit, patient needs, and potential long-term value.  TEL AVIV, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE